Juan Rodriguez-Escudero, MD
Advanced Heart Failure and Transplant Cardiology · Miami Beach, FLNPI 1699134775
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,055 of the $8,840 with a category attached, or 68.5%. 22 manufacturers reported payments, led by Abbott at 38.0% of the total. Reporting peaked in 2019 at $3,969 and has fallen 68.8% since, to $1,239 in 2025.
Across 133 payments — averaging $66.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$2K
- Abiomed$795
- Actelion Pharmaceuticals US, Inc.$710
- E.r. Squibb & Sons, L.L.C.$335
- Pfizer$296
- plus $2K from 16 others
What the payments were for
- Travel & lodging$2,72231%
- Food & beverage$6,05568%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 53 | $3,355 |
| Medtronic(2 entities) | 13 | $1,815 |
| Abiomed | 12 | $795 |
| Actelion Pharmaceuticals US, Inc. | 10 | $710 |
| E.r. Squibb & Sons, L.L.C. | 8 | $335 |
| Pfizer | 8 | $296 |
| Impulse Dynamics (USA) Inc. | 3 | $221 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $195 |
| Edwards Lifesciences | 1 | $169 |
| Novartis | 3 | $150 |
| Amgen | 2 | $141 |
| United Therapeutics Corporation | 1 | $120 |
| AstraZeneca | 2 | $107 |
| Merck | 2 | $95 |
| Akcea Therapeutics, Inc. | 1 | $84 |
| Bridgebio Pharma, Inc. | 2 | $65 |
| Sanofi | 1 | $48 |
| Boston Scientific | 3 | $46 |
| Boehringer Ingelheim | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Heartflow, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioMEMS HF System$833
- CARDIOMEMS$746
- UPTRAVI$622
- OPSUMIT$622
- Impella$280
- OPTIMIZER$223
- MitraClip$170
- PASCAL$169
- MitraClip System$163
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$162
- COREVALVE EVOLUT R$137
- ENTRESTO$125
- Repatha$122
- CAMZYOS$120
- ORENITRAM$120
- TYVASO$120
- REMODULIN$120
- HeartMate 3 Left Ventricular Dev$109
How this compares
$8,840 in reported general payments places this provider in the 55th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 157 | $3,434,686 |
| OpsumitMacitentan | 96 | $1,189,645 |
| UptraviSelexipag | 42 | $946,604 |
| VyndaqelTafamidis Meglumine | 42 | $892,621 |
| AdempasRiociguat | 30 | $434,385 |
| FarxigaDapagliflozin Propanediol | 382 | $300,036 |
| CamzyosMavacamten | 36 | $297,127 |
| EntrestoSacubitril/Valsartan | 288 | $254,005 |
| JardianceEmpagliflozin | 119 | $97,219 |
| EliquisApixaban | 112 | $96,298 |
| Ambrisentan | 26 | $85,448 |
| XareltoRivaroxaban | 23 | $21,909 |
| DapagliflozinDapagliflozin Propanediol | 22 | $14,879 |
| Sildenafil Citrate | 39 | $5,802 |
| Potassium Chloride | 153 | $5,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $296 | $4,423,605311 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $710 | $2,136,250138 claims |
| AstraZenecaFarxiga | $107 | $300,036382 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $335 | $297,12736 claims |
| NovartisEntresto | $150 | $254,005288 claims |
| Boehringer IngelheimJardiance | $38 | $97,219119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Miami Beach
- Kelly McCantsWinter Park$445K
- Naveen BellamOrlando$414K
- Phillip HabibDelray Beach$305K
- Waqas GhummanAtlantis$276K
- David SnipeliskyWeston$250K
- Elsy NavasNaples$234K
- David BaranWeston$116K
- Rohan GoswamiJacksonville$112K
- Tara Hrobowski-BlackmanLargo$102K
- Stacy MandrasOrlando$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.